Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 4.67B 701M 629M 581M 527M 984M 66.76B 996M 6.95B 2.77B 34.93B 2.63B 2.57B 111B P/E 2026 *
6.19x
P/E 2027 * 5.76x
Enterprise Value 4.67B 701M 629M 581M 527M 984M 66.76B 996M 6.95B 2.77B 34.93B 2.63B 2.57B 111B EV / Sales 2026 *
1.99x
EV / Sales 2027 * 1.99x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
1 day-21.87%
Current month-21.87%
1 month-21.87%
3 months-12.78%
6 months-12.78%
Current year-12.78%
1 month 16.79
Extreme 16.79
21.78
Current year 16.79
Extreme 16.79
22.23
1 year 16.79
Extreme 16.79
22.23
3 years 16.79
Extreme 16.79
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 01/12/2019
Comptroller/Controller/Auditor 53 01/02/2011
Director TitleAgeSince
Chairman 70 14/08/2002
Director/Board Member 58 -
Director/Board Member 50 01/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-21.87%0.00% - - 700M
+5.83%+5.07%+68.77%+142.70% 1,148B
+1.44%+2.87%+47.53%+87.23% 652B
+1.30%+1.80%+28.95%+104.61% 505B
+0.84%+2.75%+54.72%+66.97% 384B
+4.59%+0.69%+71.24%+44.39% 348B
+2.54%+3.09%+34.88%+56.99% 294B
+2.04%+0.65%+4.01%+27.85% 264B
+1.67%+3.20%+58.21%+75.39% 244B
+1.47%+2.87%+36.46%+107.92% 197B
Average +0.10%+1.39%+44.98%+79.34% 448.57B
Weighted average by Cap. +3.17%+1.50%+50.31%+93.79%

Financials

2026 *2027 *
Net sales 2.34B 352M 315M 292M 264M 493M 33.48B 499M 3.49B 1.39B 17.52B 1.32B 1.29B 55.62B 2.35B 352M 316M 292M 264M 494M 33.53B 500M 3.49B 1.39B 17.54B 1.32B 1.29B 55.7B
Net income 755M 113M 102M 93.93M 85.07M 159M 10.79B 161M 1.12B 447M 5.64B 425M 416M 17.92B 811M 122M 109M 101M 91.38M 171M 11.59B 173M 1.21B 481M 6.06B 456M 447M 19.25B
Net Debt - -
Projected Income Statement - Annual - China Shineway Pharmaceutical Group Limited
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - China Shineway Pharmaceutical Group Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.187CNY
Average target price
7.294CNY
Spread / Average Target
+17.90%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Shineway Pharmaceutical Group Limited